FDA releases silicone breast implants from tracking rules
This article was originally published in Clinica
The US FDA has exempted a number of manufacturers from its mandatory tracking requirements after concluding that their products are not risky enough to warrant the added regulatory burden. The exemption includes companies that make silicone gel implants and saline breast implants.
You may also be interested in...
Jakavi joins the likes of Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients
As China is poised to supply globally medical products to fight coronavirus, a battle to banish its image of poor product quality is on.
With finite resources, the UK’s regulatory agency responsible for health care products is rapidly addressing COVID-19 medtech issues. But shifting its focus will cause delays elsewhere.